Who is sponsoring NCT04530799?

NCT04530799 is sponsored by Radboud University Medical Center.

What drugs are being tested in NCT04530799?

Interventions in NCT04530799: Identification of biomarkers for IAPA via patient sampling.

What condition does NCT04530799 study?

NCT04530799 studies Influenza With Pneumonia, Pulmonary Aspergillosis.

Is NCT04530799 still recruiting?

NCT04530799 is currently active, enrolled. Last updated 1 April 2026.

Last reviewed 2026-04-01 · How we verify

NCT04530799: IAPAFLU

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prospective Observational Trial of IAPA

Active, enrolled Last updated 1 April 2026

What this trial tests

trial testing Identification of biomarkers for IAPA via patient sampling in Influenza With Pneumonia in 350 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

10 March 2022

Primary endpoint
30 April 2026

30 April 2026

Quick facts

Lead sponsor	Radboud University Medical Center
Status	Active, enrolled
Study type	OBSERVATIONAL
Enrollment	350
Start date	10 March 2022
Primary completion	30 April 2026
Estimated completion	30 April 2026
Sites	12 locations across Belgium, France, Netherlands

Drugs / interventions tested

Identification of biomarkers for IAPA via patient sampling

Conditions studied

Influenza With Pneumonia — all drugs for Influenza With Pneumonia →
Pulmonary Aspergillosis — all drugs for Pulmonary Aspergillosis →

Sponsor

Radboud University Medical Center

Who can join

18 and older, any sex, with Influenza With Pneumonia or Pulmonary Aspergillosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A prospective multi-center observational study to assess the incidence of influenza-associated pulmonary aspergillosis (IAPA) in ICU patients and to identify host- and pathogen related risk factors for IAPA in EORTC negative ICU patients with severe influenza.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Radboud University Medical Center trials

Trials by the same sponsor.

NCT07485569 — Drug Repurposing in Thyroid Carcinoma: a Feasibility Trial · Phase 1 · not yet recruiting
NCT07514325 — MR-guided Adaptive Stereotactic Radiotherapy for Endometrial Cancer · NA · not yet recruiting
NCT07530263 — Deposition of Inhaled Liposomal Amphotericin B in Chronic Pulmonary Aspergillosis (CPA) · Phase 1 · not yet recruiting
NCT07532577 — Intranasal Insulin to Prevent Intensive Care Unit Delirium · Phase 2, PHASE3 · not yet recruiting
NCT07504172 — Real-world Effectiveness and Dosing Patterns of Tirzepatide in People With Obesity · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04530799 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Radboud University Medical Center
Last refreshed: 1 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04530799.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing